Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|37|5676-5686

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.37, 2016-11, pp. : 5676-5686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cholesterol-lowering drugs reduce mortality risk after revascularisation

By  

Inpharma, Vol. 1, Iss. 1501, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Lowering of LDL-cholesterol may increase risk of cancer

By  

Reactions Weekly, Vol. 1, Iss. 1164, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Lipid-Lowering Therapy in Patients with Average Cholesterol and High Cardiovascular Risk, Insights from the Heart Protection Study

By Salam Amar  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 5, 2004-09 ,pp. : 387-389

Springer Publishing Company

Access to resources Recommend Favorite

Homocysteine-lowering therapy lowers risk of CHD?

By  

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Treating Ocular Hypertension to Reduce Glaucoma Risk: When to Treat?

By Higginbotham Eve J.  

Drugs, Vol. 66, Iss. 8, 2006-01 ,pp. : 1033-1039

Adis International

Access to resources Recommend Favorite